Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying
12:15am, Friday, 26'th Jun 2026
Recursion Pharmaceuticals' approach to drug discovery could advance the industry. Fiverr is implementing a strategy shift that may help it bounce back from recent headwinds.
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
06:50pm, Wednesday, 24'th Jun 2026
Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
06:51pm, Tuesday, 16'th Jun 2026
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.
Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed
12:43pm, Friday, 12'th Jun 2026
Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in solid tumors, with Q1'26 earnings noting no dose-limiting toxicities so far. Initial DHALIA trial data
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
06:50pm, Wednesday, 10'th Jun 2026
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving 5.12% from the previous trading session.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:42pm, Tuesday, 09'th Jun 2026
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
12:35pm, Friday, 05'th Jun 2026
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
05:12pm, Tuesday, 02'nd Jun 2026
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
Recursion to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 02'nd Jun 2026
Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
04:30pm, Friday, 29'th May 2026
Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, th
Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City
12:07pm, Tuesday, 19'th May 2026
Altitude Lab portfolio companies surpass $205M in funding as startups advance clinical trials, sign global pharma deals, and reshape early-stage biotech.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
05:30pm, Tuesday, 12'th May 2026
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
3 Stocks Poised to Disrupt the Healthcare Market by 2030
07:30am, Friday, 08'th May 2026
The old healthcare model is breaking down.
Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back
01:04pm, Thursday, 07'th May 2026
Earlier this year, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) initiated discussions with the FDA for the design of a registrational study for its experimental drug REC-4881 in familial adenomatous po
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
12:30pm, Thursday, 07'th May 2026
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
